Skip to main content
PMC home page
American Journal of Alzheimer's Disease and Other Dementias logoLink to American Journal of Alzheimer's Disease and Other Dementias
. 2002 Nov-Dec;17(6):338–344. doi: 10.1177/153331750201700607

Depression and Alzheimer's disease: Symptom or comorbidity?

Rita Moretti 1, Paola Torre, Rodolfo M Antonello, Giuseppe Cazzato 2, Antonio Bava 3
PMCID: PMC10833988  PMID: 12501480

Abstract

Alzheimer's disease is the most frequent form of dementia, where behavioral and cognitive disruption symptoms coexist. Depression, apathy, anxiety, and other conduct disorders are the complaints most often reported by caregivers.

Fifty subjects were referred to our Institute with a diagnosis of probable Alzheimer's disease. Cognitive impairment was equally distributed among the subjects. Patients, aged 68 to 76 years old, were randomized to receive inhibitors of cholinesterase (Donepezil, 5 mg/ day) alone, or inhibitors of cholinesterase plus selective seratonin reuptake inhibitors (SSRIs) (citalopram HBr, 20 mg/day).

We followed up all the patients for one year, with particular concern for neuropsychological aspects associated with eventual behavioral changes. Results indicate that SSRI intake seems to be effective for depression, decreasing it and improving quality of life for both patients and caregivers. Side effects in both groups were few, and there were no study withdrawals.

This paper discusses the relationship between dementia-and depression, and presents our finding that depressive symptoms, if specifically treated, tend to reduce caregiver stress and improve well-being in patients with Alzheimer's disease.

Keywords: Alzheimer's disease, citalopram, dementia, depression, serotonin, SSRIs

Full Text

The Full Text of this article is available as a PDF (97.5 KB).

Contributor Information

Rita Moretti, Dipartimento di Fisiologia e Patologia, Università degli Studi di Trieste; Dipartimento di Medicina Clinica e Neurologia, UCO di Clinica Neurologica, Sezione Disturbi Cognitivi, Università degli Studi di Trieste, Italia.

Giuseppe Cazzato, Dipartimento di Medicina Clinica e Neurologia, UCO di Clinica Neurologica, Sezione Disturbi Cognitivi, Università degli Studi di Trieste, Italia.

Antonio Bava, Dipartimento di Fisiologia e Patologia, Università degli Studi di Trieste, Italia.

References

  1. Teri L, Borson S, Kiyak A, et al.: Behavioral disturbance, cognitive dysfunction, and functional skill. Prevalence and relationship in Alzheimer's disease. J Am Geriatr. Soc. 1980; 37: 109-116. [DOI] [PubMed] [Google Scholar]
  2. Teri L, Logsdon RG, Uomoto J, et al.: Behavioral treatment of depression in dementia patients: A controlled clinical trial. J Gerontol. 1997; 52: P159-P166. [DOI] [PubMed] [Google Scholar]
  3. Cummings JL, Knopman D: Advances in treatment of behavioural disturbances in Alzheimer's Disease. Neurology. 1999; 53: 899-901. [DOI] [PubMed] [Google Scholar]
  4. Masterman D: Treatment of the psychopathology of Alzheimer's Disease (Can I change psychopathology to neuropsychiatric symptoms?), Am Acad Neurol. 2001; 6TP.001-19-33. [Google Scholar]
  5. Ernst RL, Hay JW: The US economic and social costs of Alzheimer's disease revisited. Am J Public Health. 1994; 84: 1261-1264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Mega MS, Cummings JL, Fiorello T, et al.: The spectrum of behavioural changes in Alzheimer's Disease. Neurology. 1996; 46: 130-135. [DOI] [PubMed] [Google Scholar]
  7. Devanand DP, Sano M, Tang MX, et al.: Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch Ger Psychiatr. 1996; 53: 175-182. [DOI] [PubMed] [Google Scholar]
  8. Devanand DP, Jacobs DM, Tang MX, et al.: The course of psychopathologic features in mild to moderate Alzheimer's disease. Arch Gen Psychiatry. 1997; 54: 257-263. [DOI] [PubMed] [Google Scholar]
  9. Alexopoulos G, Sliver JM, Kahn DA, et al.(eds.): Treatment of Agitation in Older Persons with Dementia: The Expert Consensus Guideline Series. McGraw-Hill: Minneapolis, MN, 1998. [A Postgraduate Medicine Special Report.] [Google Scholar]
  10. McKahnn G, Drachman D, Folstein M, et al.: Clinical diagnosis of AD: Report of the NINCS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34: 939-944. [DOI] [PubMed] [Google Scholar]
  11. Folstein M, Folstein S, McHugh P: Mini-Mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: 189-198. [DOI] [PubMed] [Google Scholar]
  12. Manos PJ: The utility of the ten-point clock test as a screen for cognitive impairment in general hospital patients. Gen Hosp Psych. 1997; 8: 469-476. [DOI] [PubMed] [Google Scholar]
  13. Wechsler D: Wechsler adult intelligence scale-R-Manual. New York: Psychological Corp., 1981. [Google Scholar]
  14. Lawton MP, Brody EM: Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist. 1969; 9: 179-189. [PubMed] [Google Scholar]
  15. Cummings JL, Mega M, Gray K, et al.: The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia. Neurology. 1994; 44: 2308-2314. [DOI] [PubMed] [Google Scholar]
  16. Hamilton M: Development of a rating scale for primary depressive illness. Br J Clin Psychol. 1967; 6: 278-296. [DOI] [PubMed] [Google Scholar]
  17. Green JG, Smith R, et al.: Measuring behavioral disturbance of elderly demented patients in the community and its effects on relatives: A factor analytic study. Age Ageing. 1982; 11: 121-131. [DOI] [PubMed] [Google Scholar]
  18. Hachinski VC: Cerebral blood flow in dementia. Arch Neurol. 1975; 32: 632-635. [DOI] [PubMed] [Google Scholar]
  19. Chung JA, Cummings JL: Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease. Dementia. 2000; 18 (4): 829-846. [DOI] [PubMed] [Google Scholar]
  20. O'Donnell BF, Drachmen DA, Barnes HJ, et al.: Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol. 1992; 5: 45-52. [DOI] [PubMed] [Google Scholar]
  21. Kaufer D: Treatment of behavioral symptoms in Alzheimer's disease. Am Acad Neurology. 2000; 5TP.001-7-19. [Google Scholar]
  22. Chemerinski E, Petracca G, Sabe L, et al.: The specificity of depressive symptoms in patients with Alzheimer's disease. Am J Psychiatry. 2001; 158: 68-72. [DOI] [PubMed] [Google Scholar]
  23. Zubenko GS, Mossy J, Martinez AJ, et al.: Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol. 1991; 48: 619-624. [DOI] [PubMed] [Google Scholar]
  24. Zweig RM, Ross CA, Hedreen JC, et al.: The neuropathology of aminergic nuclei in Alzheimer's disease. Ann Neurol. 1988; 24: 233-242. [DOI] [PubMed] [Google Scholar]
  25. Pettenati C, Donato MF, Musicco M: Behavioral symptoms of Alzheimer's disease: Improvement by Donepezil. 6th International Conference on Alzheimer's Disease and Related Disorders. Amsterdam: RAI Group, 1998. [Google Scholar]
  26. Moretti R, Torre P, Antonello RM, et al.: Rivastigmine in subcortical vascular dementia: A comparison trial on efficacy and tolerability for 12 months follow-up. Eur J Neurol. 2001; 8: 361-362. [DOI] [PubMed] [Google Scholar]
  27. Blenow KAH, Wallin A, Gottfries CG, et al.: Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease. Neurobiol Aging. 1991; 13: 107-113. [DOI] [PubMed] [Google Scholar]
  28. Nyth AL, Gottfries CG, Lyby K, et al.: A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatrica Scand. 1992, 86(2): 138-145. [DOI] [PubMed] [Google Scholar]
  29. Flint AJ, van Reekum R: The pharmachologic treatment of Alzheimer's disease: A guide for the general psychiatrist. Can J Psychiatry. 1998; 43(7): 689-697. [DOI] [PubMed] [Google Scholar]
  30. Kyle CJ, Petrsen HE, Overo KF: Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice. Depress Anxiety. 1988; 8(4): 147-153. [PubMed] [Google Scholar]
  31. Pollock BG, Mulsant BH, Sweet R, et al.: An open pilot study of citalopram for behavioral disturbances of dementia. Plasma levels and real-time observations. Am J Geriatr Psychiatry. 1997; 5(1): 70-78. [PubMed] [Google Scholar]
  32. Tohgi H, Abe T, Takahashi S, et al.: Indoleamine concentrations in cerebrospinal fluid from patients with Alzheimer type and Binswanger type dementias before and after administration of citalopram, a synthetic serotonin uptake inhibitor. J Neural Transm Park Dis Dement Sect. 1995; 9(2-3): 121-131. [DOI] [PubMed] [Google Scholar]
  33. D'Amato RJ, Zweig RM, Whitehouse PJ, et al.: Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann Neurol. 1987; 22: 229-236. [DOI] [PubMed] [Google Scholar]
  34. Eninger G, Bruyland M, Martin JJ, et al.: Distribution of biogenic amines and their catabolites in brains from patients with Alzheimer's disease. J Neurol Sci. 1987; 77: 267-283. [DOI] [PubMed] [Google Scholar]
  35. Palmer AM, Francis PT, Benson JS, et al.: Presynaptic serotoninergic dysfunction in patients with Alzheimer's disease. J Neurochem. 1987; 48: 8-15. [DOI] [PubMed] [Google Scholar]
  36. Adolfsson R, Gottfries CG, Roos BE, et al.: Changes in the brain cathecolamines in patients with AD. Br J Psych. 1979; 135: 216-223. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Alzheimer's Disease and Other Dementias are provided here courtesy of SAGE Publications

RESOURCES